PI
BTAI icon

Pennant Investors’s BioXcel Therapeutics BTAI Stock Holding History

Pennant Investors’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-5,244
Closed -$107K – 24
2024
Q2 		$107K Hold
5,244
– – 0.03% 44
2024
Q1 		$237K Hold
5,244
– – 0.06% 39
2023
Q4 		$248K Buy
+5,244
New +$292K 0.05% 40

Other funds holding BTAI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Pennant Investors's BTAI Position: Q3 2024 in Review

Pennant Investors sold out of BioXcel Therapeutics (BTAI) in Q3 2024, closing a stake of 5,244 shares — an estimated $107K sold.

Pennant Investors first reported a position in BTAI in Q4 2023 and held it in 3 quarters. The position peaked at $248K in Q4 2023. 49 funds tracked by Wall St. Rank hold BTAI as of Q3 2024.

  • Pennant Investors reported no remaining BioXcel Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Pennant Investors sold 5,244 BioXcel Therapeutics shares in Q3 2024, an estimated $107K.
  • Pennant Investors first reported a position in BioXcel Therapeutics in Q4 2023 and held it in 3 quarters.
  • Pennant Investors's BioXcel Therapeutics position peaked at $248K in Q4 2023.
  • 49 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q3 2024.

Based on Pennant Investors's 13F filing for Q3 2024, filed 14 Nov 2024.